Search results
Moderna Just Gave Investors Another Reason to Buy the Stock | The Motley Fool
The Motley Fool· 3 days agoModerna (MRNA -3.58%) is best known for its work in the coronavirus vaccine market. Let's look...
Gateway - Quartz
Quartz· 6 hours agoModerna said Tuesday that its updated COVID-19 vaccine demonstrated a stronger immune response than its current jab in results from a phase-3 clinical trial. The pharma < ...
Moderna Stock (NASDAQ:MRNA): Is There Life Beyond Disease Outbreaks?
TipRanks via Yahoo Finance· 2 days agoModerna (NASDAQ:MRNA) stock has surged 40.8% since the turn of the year. Some of this momentum can...
Moderna, Inc. (NASDAQ:MRNA) Shares Bought by Wellington Management Group LLP
ETF DAILY NEWS· 2 days agoWellington Management Group LLP lifted its holdings in shares of Moderna, Inc. (NASDAQ:MRNA – Free Report) by 28.8% in the 4th quarter, according to the company in its most ...
Moderna stock is lone omen of bird flu pandemic
Reuters· 2 days agoThe recent rise of Moderna’s stock tells a grim tale. The $56 billion company which pioneered a Covid vaccine has seen its market value rise 40% since...
Is Moderna Stock A Buy After Its Second-Ever Product Snags FDA Approval?
Investor's Business Daily· 7 days agoEarlier in the year, one analyst called results from the cancer vaccine study "transformational."...
Moderna says next-gen COVID shot effective in study
BioPharma Dive via Yahoo Finance· 6 days agoTrial data suggest the shot — an important component of an upcoming combination inoculation — has proven at least as effective, and in some cases...
Moderna's mRNA-1283 vaccine shows promise in Phase 3 trial By Investing.com
Investing.com· 6 days agoModerna , Inc. (NASDAQ:MRNA) has announced successful results from the Phase 3 trial of its...
Column: This GOP-leaning political polling firm has turned into a purveyor of anti-vaccine...
LA Times via Yahoo News· 1 hour agoBlaming the COVID vaccines for a tide of undocumented injuries and deaths is a popular theme in the...
Moderna says new-generation COVID vaccine more effective than Spikevax in adults 18 and over
Morningstar· 6 days agoModerna Inc. said Thursday a Phase 3 trial of its next-generation COVID-19 vaccine met its main goal and showed higher efficacy in adults age 18 and older compared with its ...